Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study.

ACR Open Rheumatology Pub Date : 2023-06-01 Epub Date: 2023-05-24 DOI:10.1002/acr2.11550
Maral DerSarkissian, Yuqian M Gu, Mei Sheng Duh, John Benson, Shirley P Huang, Carlyne Averell, Jensen Vu, Min-Jung Wang, Christopher F Bell
{"title":"Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study.","authors":"Maral DerSarkissian, Yuqian M Gu, Mei Sheng Duh, John Benson, Shirley P Huang, Carlyne Averell, Jensen Vu, Min-Jung Wang, Christopher F Bell","doi":"10.1002/acr2.11550","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To characterize health care resource utilization (HCRU), health care costs, and adverse events (AEs) among patients with systemic lupus erythematosus (SLE) initiating oral corticosteroids (OCS) versus patients without OCS use.</p><p><strong>Methods: </strong>In this retrospective cohort study (GSK Study 213061), eligible patients (aged ≥5 years at first OCS claim) with SLE from the IQVIA Real-World Data Adjudicated Claims-US database (January 2006 to July 2019) had continuous enrollment during the 6-month preindex (baseline) and 12-month postindex (observation) periods and one or more inpatient or emergency department SLE diagnosis codes or two or more outpatient SLE diagnosis codes during baseline. The \"OCS-initiator cohort\" comprised patients with one or more OCS pharmacy claims during the study period and no evidence of preindex OCS use and was classified into three exposure categories based on the number of 6-month periods of more than 5 mg/day of OCS use (0, 1, 2). The \"no-OCS-use cohort\" comprised patients without OCS claims, although patients may have received OCS prior to the study period. Clinical and economic outcomes were reported over the observation period.</p><p><strong>Results: </strong>Adjusted health care costs differed significantly ($6542 [95% confidence interval (CI): $5761-$7368], $19,149 [95% CI: $16,954-$21,471], $28,985 [95% CI: $25,546-$32,885]). HCRU incidence rates were significantly greater for all OCS-initiator exposure categories (n = 16,216) versus the no-OCS-use cohort (n = 11,137; adjusted incidence rate ratios [95% CI]: 1.22 [1.19-1.24], 1.39 [1.34-1.43], 1.66 [1.60-1.73]). OCS-related AEs were experienced by 67.1% to 74.1% of patients with OCS initiation, most commonly affecting the immune system.</p><p><strong>Conclusion: </strong>Within 12 months of OCS initiation, patients with SLE experienced substantial clinical and economic burden, which may imply a need to minimize OCS use.</p>","PeriodicalId":7084,"journal":{"name":"ACR Open Rheumatology","volume":"5 6","pages":"318-328"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e6/cf/ACR2-5-318.PMC10267805.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACR Open Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/acr2.11550","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/24 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To characterize health care resource utilization (HCRU), health care costs, and adverse events (AEs) among patients with systemic lupus erythematosus (SLE) initiating oral corticosteroids (OCS) versus patients without OCS use.

Methods: In this retrospective cohort study (GSK Study 213061), eligible patients (aged ≥5 years at first OCS claim) with SLE from the IQVIA Real-World Data Adjudicated Claims-US database (January 2006 to July 2019) had continuous enrollment during the 6-month preindex (baseline) and 12-month postindex (observation) periods and one or more inpatient or emergency department SLE diagnosis codes or two or more outpatient SLE diagnosis codes during baseline. The "OCS-initiator cohort" comprised patients with one or more OCS pharmacy claims during the study period and no evidence of preindex OCS use and was classified into three exposure categories based on the number of 6-month periods of more than 5 mg/day of OCS use (0, 1, 2). The "no-OCS-use cohort" comprised patients without OCS claims, although patients may have received OCS prior to the study period. Clinical and economic outcomes were reported over the observation period.

Results: Adjusted health care costs differed significantly ($6542 [95% confidence interval (CI): $5761-$7368], $19,149 [95% CI: $16,954-$21,471], $28,985 [95% CI: $25,546-$32,885]). HCRU incidence rates were significantly greater for all OCS-initiator exposure categories (n = 16,216) versus the no-OCS-use cohort (n = 11,137; adjusted incidence rate ratios [95% CI]: 1.22 [1.19-1.24], 1.39 [1.34-1.43], 1.66 [1.60-1.73]). OCS-related AEs were experienced by 67.1% to 74.1% of patients with OCS initiation, most commonly affecting the immune system.

Conclusion: Within 12 months of OCS initiation, patients with SLE experienced substantial clinical and economic burden, which may imply a need to minimize OCS use.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
系统性红斑狼疮患者口服皮质类固醇后第一年的临床和经济负担:一项回顾性美国数据库研究。
目的描述开始使用口服皮质类固醇(OCS)的系统性红斑狼疮(SLE)患者与未使用OCS的患者之间的医疗资源利用率(HCRU)、医疗费用和不良事件(AEs)的特征:在这项回顾性队列研究(葛兰素史克研究 213061)中,IQVIA Real-World Data Adjudicated Claims-US 数据库(2006 年 1 月至 2019 年 7 月)中符合条件的系统性红斑狼疮患者(首次申请 OCS 时年龄≥5 岁)在指标前 6 个月(基线)和指标后 12 个月(观察)期间连续注册,并且在基线期间有一个或多个住院或急诊科系统性红斑狼疮诊断代码或两个或多个门诊系统性红斑狼疮诊断代码。OCS启动者队列 "包括在研究期间有一份或多份OCS药房报销单且无证据表明在研究前使用过OCS的患者,并根据6个月内每天使用OCS超过5毫克的次数分为三个暴露类别(0、1、2)。未使用 OCS 队列 "包括未申请 OCS 的患者,尽管患者可能在研究期间之前使用过 OCS。在观察期间报告了临床和经济结果:调整后的医疗费用差异显著(6542 美元 [95% 置信区间 (CI):5761-7368 美元]、19149 美元 [95% CI:16954-21471 美元]、28985 美元 [95% CI:25546-32885 美元])。与未使用 OCS 的队列(n = 11,137; 调整后的发病率比 [95% CI],1.22 [1.19-1.19]] 相比,所有 OCS 启动者暴露类别(n = 16,216 人)的 HCRU 发病率明显更高:1.22 [1.19-1.24], 1.39 [1.34-1.43], 1.66 [1.60-1.73]).67.1%至74.1%的患者在开始使用OCS时出现了与OCS相关的AE,最常见的是影响免疫系统:结论:在开始使用OCS的12个月内,系统性红斑狼疮患者承受了巨大的临床和经济负担,这可能意味着需要尽量减少OCS的使用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Redox Pathogenesis in Rheumatic Diseases. Treatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota. CD14+ Dendritic-Shaped Cells Functioning as Dendritic Cells in Rheumatoid Arthritis Synovial Tissues. Patient-Led Urate Self-Monitoring to Improve Clinical Outcomes in People With Gout: A Feasibility Study. Detection and Grading of Radiographic Hand Osteoarthritis Using an Automated Machine Learning Platform.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1